|
... Frequency and/or urgency of urination; Unusual fatigue; Shortness of breath; New and unexplained abnormal postmenopausal vaginal bleeding. The risk for ovarian cancer increases with age, with the highest occurrence in women over 50 years old. A ...
|
|
... "These analyses indicate that Divigel(R) (estradiol gel) 0.1% is a valuable alternative for certain postmenopausal women with moderate to severe hot flashes," said Ronald Ackerman, MD, FACOG, CEO and principal investigator, Comprehensive Clinical ...
|
|
... one late-stage study presented Thursday at The North American Menopause Society conference in Orlando, Fla., postmenopausal women getting various doses of Aprela had the same rates of breast tenderness and abnormal mammograms as the groups getting ...
|
|
... voted 9-3 on Sept. 8 that the benefits of Fablyn could outweigh its risks, including blood clots and vaginal bleeding, for some women. The FDA is not required to follow the advice of its advisers, though it often does. Some panelists said the drug's ...
|
|
Abstract OBJECTIVE: The purpose of this study was to determine the value of screening transvaginal ultrasonography for the evaluation of endometrial abnormalities in women with postmenopausal bleeding.
|
|
... than those taking placebo. Pfizer, the world's largest drugmaker, is seeking approval to market Fablyn to postmenopausal women with osteoporosis, which can cause debilitating bone fractures and thinning. The FDA posted its review of the drug online ...
|